drugset / Trial / NCT04276376
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate
Timeline
- Start
- 2019-04-12
- Primary completion
- 2023-01-25
- Completion
- 2023-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Subject | Rucaparib | Small molecule | 600 mg | — |